Multiple Endocrine Neoplasia Type 1

Menin is a protein encoded by the MEN1 gene and plays a crucial role in the human body. It acts as a tumor suppressor and is involved in regulating cell growth and division. Menin interacts with various proteins and transcription factors to control gene expression, particularly those involved in cell cycle regulation and DNA repair. Mutations in the MEN1 gene can lead to the development of multiple endocrine neoplasia type 1 (MEN1) syndrome, a hereditary disorder characterized by the formation of tumors in various endocrine organs. Understanding the role of menin is essential for developing targeted therapies and improving treatment options for MEN1 syndrome and related conditions. Menin is the expression product of the MEN1 gene, which causes multiple endocrine neoplasia. Multiple endocrine neoplasia syndrome is a familial autosomal dominant disease characterized by endocrine organ tumors such as parathyroid, islet, and anterior pituitary tumors. The occurrence of facial vascular fibromas, gliomas, and lipomas is also related to MEN1. Studies have shown that abnormal expression of Menin is related to the occurrence of diseases such as leukemia and diabetes. The mechanism of mutation promoting tumor formation is mainly through the functional loss of both alleles, causing minor mutations such as missense mutations, or larger mutations such as heterozygous loss. More than 400 types of MEN1 mutations have been found in mammals and microorganisms, most of which are nonsense mutations and frameshift mutations. These two mutations lead to the shortening or inactivation of the encoded gene, thereby changing the key function of Menin inhibiting tumor activity. In islet cells, Menin mutations will lead to excessive proliferation of β cells and the formation of islet β cell tumors. Overexpression of Menin can block the proliferation process of β cells, leading to a relative lack of insulin secretion. Based on the analysis of the provided data, Syndax Pharmaceuticals, Inc. is the company with the highest stage of development on the target menin. The indications for drugs targeting menin cover a wide range of diseases, including various types of leukemia, solid tumors, and other cancers. Small molecule drugs and chemical drugs are progressing rapidly, indicating intense competition in the development of innovative drugs. The United States, China, and several European countries are actively developing drugs targeting menin. China, in particular, has shown progress in both Phase 1/2 and preclinical stages. Overall, the target menin presents a competitive landscape with potential for future development in the pharmaceutical industry. How do they work?Menin inhibitors are a type of drug that target the protein called menin. Menin is a protein that is encoded by the MEN1 gene and plays a role in regulating gene expression. Inhibiting menin can have therapeutic effects in certain diseases, particularly in the context of cancer. From a biomedical perspective, menin inhibitors are being studied and developed as potential treatments for various types of cancer. By inhibiting menin, these drugs aim to disrupt the abnormal gene expression patterns that contribute to cancer growth and progression. Menin inhibitors have shown promise in preclinical studies and early-phase clinical trials, particularly in the treatment of certain types of leukemia and other solid tumors. It is important to note that menin inhibitors are still under investigation and have not yet been approved as standard treatments for cancer. Further research is needed to fully understand their efficacy, safety, and potential side effects. List of menin InhibitorsThe currently marketed menin inhibitors include: RevumenibDS-1594ZiftomenibBMF-219BN-104BN-104Mi-003BNM-1192D0060-319DS-M1 (Daiichi Sankyo)For more information, please click on the image below. What are menin inhibitors used for?Menin inhibitors have shown promise in preclinical studies and early-phase clinical trials, particularly in the treatment of certain types of leukemia and other solid tumors. For more information, please click on the image below to log in and search. How to obtain the latest development progress of menin inhibitors?In the Synapse database, you can keep abreast of the latest research and development advances of menin inhibitors anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

Menin is an expression product of the tumorigenic gene MEN1 in multiple endocrine neoplasia. Multiple endocrine neoplasia syndrome is a familial autosomal dominant disease characterized by endocrine organ tumors such as thyroid, pancreatic islets, and anterior pituitary tumors. The occurrence of facial vascular fibroma, glioma, and lipomas are also related to MEN1.  Studies show that abnormal Menin expression is associated with the occurrence of diseases such as leukemia and diabetes. The mechanism by which mutations promote tumor formation is mainly through the loss of function of the two alleles, causing minor mutations such as missense mutations, or larger mutations such as heterozygous loss. More than 400 types of MEN1 mutations have been found in mammals and microorganisms, most of which are nonsense mutations and frameshift mutations. These two types of mutations lead to shortened gene encoding or inactivation of Menin, thereby changing the key function of Menin in inhibiting tumor activity. In pancreatic islet cells, Menin mutations will lead to excessive proliferation of β cells and result in islet β-cell tumors. Excessive Menin expression levels can obstruct the proliferation process of β cells, leading to relatively insufficient insulin secretion. Menin is a protein encoded by the MEN1 gene and plays a crucial role in the human body. It acts as a tumor suppressor and is primarily found in the nucleus of cells. Menin is involved in regulating gene expression, cell division, and DNA repair processes. It interacts with various proteins and transcription factors to control cell growth and differentiation. Mutations in the MEN1 gene can lead to the development of multiple endocrine neoplasia type 1 (MEN1) syndrome, a hereditary disorder characterized by the formation of tumors in various endocrine organs. Understanding the role of menin is essential for developing targeted therapies for MEN1 syndrome and other related conditions. MENIN Competitive LandscapeAccording to Patsnap Synapse, as of 13 Oct 2023, there are a total of 18 menin drugs worldwide, from 16 organizations, covering 31 indications, and conducting 23 clinical trials.  👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs , indications, organizations, clinical trials, clinical results, and drug patents related to this target. The analysis of the target menin in the pharmaceutical industry reveals a competitive landscape with multiple companies actively pursuing R&D in this area. The highest stage of development is Phase 2, indicating promising progress in the development of drugs targeting menin. Indications such as various types of leukemia, diabetes mellitus type 2, solid tumors, and lymphomas highlight the potential therapeutic applications of these drugs. Small molecule drugs and chemical drugs are progressing rapidly, indicating intense competition and the need for further analysis of biosimilars. The United States, China, and several European countries are leading in terms of R&D progress, with China showing significant progress in recent years. Overall, the target menin presents a promising area for future development in the pharmaceutical industry. Key drug: BMF-219BMF-219 is a small molecule drug developed by Biomea Fusion, Inc. It is designed to target menin, a protein involved in various cellular processes. The drug is currently in the highest phase of clinical development, Phase 1/2, indicating that it has progressed beyond preclinical studies and is being tested in human subjects. The therapeutic areas that BMF-219 aims to address are diverse, spanning across Immune System Diseases, Endocrinology and Metabolic Disease, Neoplasms, Cardiovascular Diseases, Digestive System Disorders, Hemic and Lymphatic Diseases, and Respiratory Diseases. This suggests that the drug has the potential to be used in the treatment of a wide range of conditions. The active indications for BMF-219 include Diabetes Mellitus, Type 2, KRAS mutant Non-small Cell Lung Cancer, metastatic non-small cell lung cancer, Non-small cell lung cancer stage III, Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Solid Tumors, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, B-Cell Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma, and Diabetes Mellitus, Type 1. This extensive list suggests that BMF-219 has the potential to be a broad-spectrum therapeutic agent. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. As the drug is currently in Phase 1/2, it is still undergoing clinical trials to evaluate its safety, efficacy, and optimal dosage. Phase 1/2 trials typically involve a small number of participants and aim to determine the drug's tolerability, dosage range, and potential side effects. If the results from these trials are promising, the drug may progress to later phases of clinical development. Biomea Fusion, Inc. is the originator organization behind BMF-219. As the developer of the drug, they hold the intellectual property rights and are responsible for its research, development, and commercialization. In summary, BMF-219 is a small molecule drug developed by Biomea Fusion, Inc. that targets menin. It is currently in Phase 1/2 of clinical development and has the potential to be used in the treatment of various diseases across multiple therapeutic areas. Further clinical trials will determine its safety and efficacy, and if successful, it may progress to later stages of development.